WO2005104745A3 - Muscarinic acetylcholine receptor antagonists - Google Patents

Muscarinic acetylcholine receptor antagonists Download PDF

Info

Publication number
WO2005104745A3
WO2005104745A3 PCT/US2005/014386 US2005014386W WO2005104745A3 WO 2005104745 A3 WO2005104745 A3 WO 2005104745A3 US 2005014386 W US2005014386 W US 2005014386W WO 2005104745 A3 WO2005104745 A3 WO 2005104745A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
receptor antagonists
acetylcholine receptor
muscarinic acetylcholine
muscarinic
methods
Prior art date
Application number
PCT/US2005/014386
Other languages
French (fr)
Other versions
WO2005104745A2 (en )
Inventor
Dramane I Laine
Michael R Palovich
Brent W Mccleland
Christopher E Neipp
Sonia M Thomas
Original Assignee
Glaxo Group Ltd
Dramane I Laine
Michael R Palovich
Brent W Mccleland
Christopher E Neipp
Sonia M Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Abstract

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
PCT/US2005/014386 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists WO2005104745A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US56562304 true 2004-04-27 2004-04-27
US60/565,623 2004-04-27

Applications Claiming Priority (36)

Application Number Priority Date Filing Date Title
BRPI0510170A BRPI0510170A (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
PT12170402T PT2570128T (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
PL12170402T PL2570128T3 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
DK05746609T DK1740177T3 (en) 2004-04-27 2005-04-27 Antagonists to muskarinfølsomme acetylcholine
US11568330 US7498440B2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
EA200601991A EA015033B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
CA 2564742 CA2564742C (en) 2004-04-27 2005-04-27 Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
KR20117001909A KR101152032B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
EP20050746609 EP1740177B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
ES05746609T ES2392848T4 (en) 2004-04-27 2005-04-27 Muscarinic antagonists acetylcholine receptors
JP2007510915A JP5014121B2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonist
EP20120170402 EP2570128B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
NZ54999705A NZ549997A (en) 2004-04-27 2005-04-27 Quinuclidine derivatives such as 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide as muscarinic acetylcholine receptor antagonists
AU2005237576A AU2005237576B2 (en) 2004-04-27 2005-04-27 Muscarinic Acetylcholine Receptor Antagonists
DK12170402T DK2570128T3 (en) 2004-04-27 2005-04-27 Antagonists to muskarinerg acetylcholine.
ES12170402T ES2600405T3 (en) 2004-04-27 2005-04-27 Muscarinic receptor antagonists acetylcholine
AP200603746A AP2213A (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists.
MXPA06012405A MXPA06012405A (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists.
HUE031304T2 HUE031304T2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
IL17815206A IL178152A (en) 2004-04-27 2006-09-18 4-[hydroxy(diphenyl)methyl]-1-{2-[phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2] octane bromide useful for treating muscarinic acetylcholine receptor mediated diseases, and pharmaceutical compositions comprising it
ECSP066940A ECSP066940A (en) 2004-04-27 2006-10-20 Muscarinic receptor antagonists acetylcholine
NO20065417A NO20065417L (en) 2004-04-27 2006-11-24 muscarinic acetylkolinreceptorantagonister
HK07106891A HK1102423A1 (en) 2004-04-27 2007-06-27 Muscarinic acetylcholine receptor antagonists
US11774867 US7488827B2 (en) 2004-04-27 2007-07-09 Muscarinic acetylcholine receptor antagonists
US12353436 US8183257B2 (en) 2004-04-27 2009-01-14 Muscarinic acetylcholine receptor antagonists
US13401890 US8309572B2 (en) 2004-04-27 2012-02-22 Muscarinic acetylcholine receptor antagonists
US13627007 US8575347B2 (en) 2004-04-27 2012-09-26 Muscarinic acetylcholine receptor antagonists
HRP20120832T1 HRP20120832T1 (en) 2004-04-27 2012-10-15 Muscarinic acetylcholine receptor antagonists
US14052816 US8853404B2 (en) 2004-04-27 2013-10-14 Muscarinic acetylcholine receptor antagonists
US14476940 US9045469B2 (en) 2004-04-27 2014-09-04 Muscarinic acetylcholine receptor antagonists
NL300694C NL300694I1 (en) 2004-04-27 2014-10-02
US14707543 US9144571B2 (en) 2004-04-27 2015-05-08 Muscarinic acetylcholine receptor antagonists
US14849775 US20160002220A1 (en) 2004-04-27 2015-09-10 Muscarinic acetylcholine receptor antagonists
CY161101008T CY1118082T1 (en) 2004-04-27 2016-10-10 COMPETITORS muscarinic receptor aketylocholinis
HRP20161385T1 HRP20161385T1 (en) 2004-04-27 2016-10-25 Muscarinic acetylcholine receptor antagonists
NO2017018C NO2017018I2 (en) 2004-04-27 2017-05-04 umeklidiniumbromid

Related Child Applications (6)

Application Number Title Priority Date Filing Date
US11568330 A-371-Of-International
US11568330 A-371-Of-International US7498440B2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
EP20120170402 Previously-Filed-Application EP2570128B1 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists
US56833007 A-371-Of-International 2007-05-03 2007-05-03
US11774867 Continuation US7488827B2 (en) 2004-04-27 2007-07-09 Muscarinic acetylcholine receptor antagonists
US12353436 Division US8183257B2 (en) 2004-04-27 2009-01-14 Muscarinic acetylcholine receptor antagonists

Publications (2)

Publication Number Publication Date
WO2005104745A2 true WO2005104745A2 (en) 2005-11-10
WO2005104745A3 true true WO2005104745A3 (en) 2006-08-03

Family

ID=35242158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014386 WO2005104745A3 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Country Status (11)

Country Link
US (9) US7498440B2 (en)
EP (3) EP2570128B1 (en)
JP (2) JP5014121B2 (en)
KR (2) KR101152032B1 (en)
CN (2) CN102040602A (en)
CA (2) CA2564742C (en)
DK (2) DK1740177T3 (en)
ES (2) ES2600405T3 (en)
LU (1) LU92565I2 (en)
NL (1) NL300694I1 (en)
WO (1) WO2005104745A3 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1897947A (en) * 2003-10-17 2007-01-17 葛兰素集团有限公司 Muscarinic acetylcholine receptor antagonists field of the invention
EP1725236A4 (en) * 2004-03-11 2009-05-13 Glaxo Group Ltd Novel m3 muscarinic acetylcholine receptor antagonists
JP2007529511A (en) * 2004-03-17 2007-10-25 グラクソ グループ リミテッドGlaxo Group Limited M3 muscarinic acetylcholine receptor antagonist
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
DE602005009158D1 (en) * 2004-04-05 2008-10-02 Samaritan Pharmaceuticals Inc Anti-hiv-chinuklidinverbindungen
WO2005112644A3 (en) * 2004-05-13 2006-03-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1957075A4 (en) * 2004-11-15 2009-11-18 Glaxo Group Ltd Novel m3 muscarinic acetylcholine receptor antagonists
JP2009503099A (en) * 2005-08-02 2009-01-29 グラクソ グループ リミテッドGlaxo Group Limited M3 muscarinic acetylcholine receptor antagonist
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
US8178573B2 (en) 2006-04-20 2012-05-15 Glaxo Group Limited Compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
JP2009545579A (en) 2006-08-01 2009-12-24 グラクソ グループ リミテッドGlaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as pde4 inhibitors
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
EP3260453A1 (en) 2009-04-30 2017-12-27 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
US8742131B2 (en) * 2010-01-28 2014-06-03 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
CA2803418A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20140116434A1 (en) 2011-06-08 2014-05-01 Glaxo Group Limited Dry Powder Inhaler Compositions
CN104470503A (en) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 Aggregate particles
RU2502743C1 (en) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Synthetic antigen having ability to fix autoantibodies to muscarine m2-receptor
EP2885298B1 (en) * 2012-08-15 2018-06-13 Glaxo Group Limited Chemical process
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
WO2015007073A1 (en) * 2013-07-13 2015-01-22 北京市丰硕维康技术开发有限责任公司 Quinine compounds, and optical isomers, preparation method and medical use thereof
EP3027184A1 (en) * 2013-07-30 2016-06-08 GlaxoSmithKline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
KR20160062179A (en) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Pi3k inhibitor for treatment of respiratory disease
US20170189424A1 (en) 2014-05-28 2017-07-06 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
JP2017534686A (en) 2014-11-03 2017-11-24 オロン ソシエタ ペル アチオニOlon Spa 1- (2-halogen - ethyl) -4 preparation of piperidine carboxylic acid ethyl ester
KR101613245B1 (en) 2015-04-27 2016-04-18 주식회사 대웅제약 Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
CN105461710A (en) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 Preparation method of umeclidinium bromide
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (en) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
NL8601949A (en) 1985-07-30 1987-02-16 Glaxo Group Ltd Devices for administering medicaments to patients.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa New quinuclidine derivatives and pharmaceutical compositions containing them.
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (en) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Pyrrolidinium novel.
ES2204295B1 (en) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. New quinuclidine amide derivatives.
WO2004091482A3 (en) 2003-04-07 2004-12-23 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
CN1897947A (en) 2003-10-17 2007-01-17 葛兰素集团有限公司 Muscarinic acetylcholine receptor antagonists field of the invention
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US20070179131A1 (en) 2004-03-11 2007-08-02 Jian Jin Novel M3 Muscarinic Acetylcholine Receptor Antagonists
EP1725236A4 (en) 2004-03-11 2009-05-13 Glaxo Group Ltd Novel m3 muscarinic acetylcholine receptor antagonists
EP1725240A4 (en) 2004-03-17 2009-03-25 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US20070185088A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen M3 muscarinic acetylchoine receptor antagonists
JP2007529511A (en) 2004-03-17 2007-10-25 グラクソ グループ リミテッドGlaxo Group Limited M3 muscarinic acetylcholine receptor antagonist
WO2005099706A3 (en) 2004-04-07 2006-05-11 Noemie Buffet Muscarinic acetylcholine receptor antagonists
WO2005112644A3 (en) 2004-05-13 2006-03-30 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2008501020A (en) 2004-05-28 2008-01-17 グラクソ グループ リミテッドGlaxo Group Limited Muscarinic acetylcholine receptor antagonist
EP1765339A4 (en) 2004-06-30 2009-09-02 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20070293531A1 (en) 2004-08-05 2007-12-20 Jakob Busch-Petersen Muscarinic Acetycholine Receptor Antagonists
EP1781103A4 (en) 2004-08-06 2008-05-14 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20090258858A1 (en) 2004-10-29 2009-10-15 Jakob Busch-Petersen Muscarinic acetylcholine receptor antagonists
WO2006055503A3 (en) 2004-11-15 2006-08-03 Brian W Budzik Novel m3 muscarinic acetylcholine receptor antagonists
EP1957075A4 (en) 2004-11-15 2009-11-18 Glaxo Group Ltd Novel m3 muscarinic acetylcholine receptor antagonists
WO2006065755A3 (en) 2004-12-13 2006-10-12 Jakob Busch-Petersen Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2006065788A3 (en) 2004-12-13 2006-08-17 Glaxo Group Ltd Novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007016650A3 (en) 2005-08-02 2007-05-31 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
JP2009503099A (en) 2005-08-02 2009-01-29 グラクソ グループ リミテッドGlaxo Group Limited M3 muscarinic acetylcholine receptor antagonist
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IKEDA K. ET AL.: 'M3 receptor angagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland' NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL. vol. 366, 2002, pages 97 - 103, XP003001709 *
See also references of EP1740177A2 *

Also Published As

Publication number Publication date Type
CN102040602A (en) 2011-05-04 application
KR101152032B1 (en) 2012-06-11 grant
KR20110010841A (en) 2011-02-07 application
CA2564742A1 (en) 2005-11-10 application
US20140371264A1 (en) 2014-12-18 application
WO2005104745A2 (en) 2005-11-10 application
NL300694I1 (en) 2015-12-29 grant
US8575347B2 (en) 2013-11-05 grant
CA2564742C (en) 2012-01-10 grant
ES2600405T3 (en) 2017-02-08 grant
US20070185155A1 (en) 2007-08-09 application
US8309572B2 (en) 2012-11-13 grant
ES2392848T4 (en) 2014-10-01 grant
LU92565I2 (en) 2014-12-02 grant
US20130030015A1 (en) 2013-01-31 application
JP5014121B2 (en) 2012-08-29 grant
JP2012162559A (en) 2012-08-30 application
ES2392848T3 (en) 2012-12-14 grant
US20090124653A1 (en) 2009-05-14 application
DK1740177T3 (en) 2012-10-29 grant
CA2755954C (en) 2014-02-18 grant
US20120157491A1 (en) 2012-06-21 application
DK2570128T3 (en) 2016-11-07 grant
KR101037026B1 (en) 2011-05-25 grant
CA2755954A1 (en) 2005-11-10 application
KR20070015412A (en) 2007-02-02 application
EP3111936A1 (en) 2017-01-04 application
JP5398871B2 (en) 2014-01-29 grant
EP2570128A1 (en) 2013-03-20 application
US7498440B2 (en) 2009-03-03 grant
JP2007534769A (en) 2007-11-29 application
EP1740177A4 (en) 2010-05-05 application
EP2570128B1 (en) 2016-08-10 grant
US8853404B2 (en) 2014-10-07 grant
EP1740177A2 (en) 2007-01-10 application
US9045469B2 (en) 2015-06-02 grant
US20160002220A1 (en) 2016-01-07 application
NL300694I2 (en) 2015-12-29 grant
CN1976701A (en) 2007-06-06 application
EP1740177B1 (en) 2012-08-08 grant
US20150238470A1 (en) 2015-08-27 application
US20070249664A1 (en) 2007-10-25 application
US20140080863A1 (en) 2014-03-20 application
US9144571B2 (en) 2015-09-29 grant
US7488827B2 (en) 2009-02-10 grant
US8183257B2 (en) 2012-05-22 grant

Similar Documents

Publication Publication Date Title
WO2007140371A8 (en) Antibodies and immunoconjugates and uses therefor
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2006050477A3 (en) Anti-microbial compositions and methods of making and using the same
GB0400352D0 (en) Restrictor
GB2420313B (en) Geomembrane
EP2004688B8 (en) Improved protofibril selective antibodies and the use thereof

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

WWE Wipo information: entry into national phase

Ref document number: 2005237576

Country of ref document: AU

Ref document number: 200607695

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2006/003746

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 178152

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 5413/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12006501850

Country of ref document: PH

Ref document number: 549997

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005746609

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005237576

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2005237576

Country of ref document: AU

Date of ref document: 20050427

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 06108728

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020067022276

Country of ref document: KR

Ref document number: PA/a/2006/012405

Country of ref document: MX

Ref document number: 2564742

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007510915

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: DE

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1200601950

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200601991

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200580021536.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005746609

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067022276

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11568330

Country of ref document: US

Ref document number: 2007185155

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11568330

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: PI0510170

Country of ref document: BR